Open AccessCertolizumab Can Also Be Effective in Monotherapy for the Treatment of Rheumatoid Arthritis Patients
Author(s) -
P. Santos-Moreno,
Susan Martínez,
Linda Ibatá,
L. Villarreal,
Manuel Rivero,
Adriana Rojas-Villarraga
Publication year - 2021
Publication title -
biologics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 38
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.s322860
Subject(s) - medicine , rheumatoid arthritis , leflunomide , certolizumab pegol , methotrexate , combination therapy , retrospective cohort study , cohort , adalimumab
Although it is known that methotrexate (MTX) increases the effectiveness of biological drugs (mainly anti-TNFs) in patients with rheumatoid arthritis (RA), in real life, it is known that many patients using anti-TNFs are on monotherapy due to many causes. This article compares the effectiveness of certolizumab as monotherapy as combined with MTX or leflunomide (LFN) in RA patients with failure to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in a real-world setting.